Zhu Y, Carmeliet P, Fay W P
Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, Michigan, USA.
Circulation. 1999 Jun 15;99(23):3050-5. doi: 10.1161/01.cir.99.23.3050.
Platelet-rich thrombi are resistant to lysis by tissue plasminogen activator (tPA). Plasminogen activator inhibitor-1 (PAI-1), a rapid inhibitor of tPA, may contribute to arterial thrombolysis resistance. However, few data are available regarding the effect of PAI-1 on arterial thrombolysis in animals. We used a murine carotid injury model to test the hypothesis that PAI-1 inhibits thrombolysis mediated by pharmacological concentrations of tPA.
Platelet-rich thrombi were induced in wild-type mice (PAI-1 +/+; n=11) and PAI-1-deficient mice (PAI-1 -/-; n=11) with ferric chloride. Baseline carotid blood flows and mean occlusion times did not differ between PAI-1 +/+ and PAI-1 -/- mice. Clot lysis was induced by infusion of heparin (200 U/kg bolus, 70 U. kg-1. h-1 drip), human plasminogen (50 mg/kg), and tPA at 20 (n=10) or 100 (n=12) microg. kg-1. min-1. Mean plasma tPA antigens were 2.7 microg/mL (tPA infusion, 20 microg. kg-1. min-1) and 5.5 microg/mL (tPA infusion, 100 microg. kg-1. min-1), with no significant differences between PAI-1 +/+ mice and PAI-1 -/- mice. Reperfusion after tPA 20 microg. kg-1. min-1 occurred in 1 of 5 PAI-1 +/+ mice versus 5 of 5 PAI-1 -/- mice (P=0.0006). Reperfusion occurred in all mice that received tPA 100 microg. kg-1. min-1, but reperfusion times were significantly shorter in PAI-1 -/- mice (17. 8+/-2.6 minutes, n=6) than in PAI-1 +/+ mice (35.7+/-5.1 minute, n=6; P=0.01). Histological analyses confirmed that carotid thrombi were platelet rich and that PAI-1 was distributed uniformly throughout thrombi from PAI-1 +/+ mice. Lysates of PAI-1 +/+ platelets inhibited human tPA, whereas PAI-1 -/- platelet lysates did not.
PAI-1 is a major determinant of the resistance of platelet-rich arterial thrombi to lysis by pharmacological concentrations of tPA. Strategies to inhibit or resist PAI-1 may enhance thrombolysis.
富含血小板的血栓对组织型纤溶酶原激活剂(tPA)介导的溶栓具有抗性。纤溶酶原激活剂抑制剂-1(PAI-1)是tPA的快速抑制剂,可能导致动脉溶栓抵抗。然而,关于PAI-1对动物动脉溶栓作用的数据很少。我们使用小鼠颈动脉损伤模型来检验PAI-1抑制药理学浓度tPA介导的溶栓这一假设。
用氯化铁在野生型小鼠(PAI-1 +/+;n = 11)和PAI-1基因缺陷小鼠(PAI-1 -/-;n = 11)中诱导形成富含血小板的血栓。PAI-1 +/+和PAI-1 -/-小鼠的基线颈动脉血流和平均闭塞时间没有差异。通过输注肝素(200 U/kg推注,70 U·kg-1·h-1滴注)、人纤溶酶原(50 mg/kg)和20(n = 10)或100(n = 12)μg·kg-1·min-1的tPA诱导血栓溶解。平均血浆tPA抗原分别为2.7 μg/mL(tPA输注,20 μg·kg-1·min-1)和5.5 μg/mL(tPA输注,100 μg·kg-1·min-1),PAI-1 +/+小鼠和PAI-1 -/-小鼠之间无显著差异。tPA 20 μg·kg-1·min-1输注后,5只PAI-1 +/+小鼠中有1只再灌注,而5只PAI-1 -/-小鼠中有5只再灌注(P = 0.0006)。接受tPA 100 μg·kg-1·min-1的所有小鼠均发生再灌注,但PAI-1 -/-小鼠的再灌注时间(17.8±2.6分钟,n = 6)明显短于PAI-1 +/+小鼠(35.7±5.1分钟,n = 6;P = 0.01)。组织学分析证实颈动脉血栓富含血小板,且PAI-1在PAI-1 +/+小鼠的血栓中均匀分布。PAI-1 +/+血小板裂解物可抑制人tPA,而PAI-1 -/-血小板裂解物则不能。
PAI-1是富含血小板的动脉血栓对药理学浓度tPA溶栓产生抗性的主要决定因素。抑制或抵抗PAI-1的策略可能会增强溶栓效果。